Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kilitch Drugs (India) Limited (KILITCH.NS)
Mumbai, IN
Kilitch Drugs (India) Limited, established in 1978 and based in Mumbai, operates a comprehensive pharmaceutical enterprise involved in the development and distribution of a wide array of medicinal and related products, both within India and for export. Their extensive portfolio includes a broad spectrum of parenteral and nasal formulations, addressing various therapeutic categories such as gastroenterology, anti-inflammatory conditions, epilepsy, malaria, and infections, among others. These are available in diverse formats like ampoules, vials, and dry powder injectables, and feature specialized offerings like iron supplements, metered nasal drops, and proprietary brands such as Klavmox and Onecef. The company also manufactures a variety of oral medications, including tablets, capsules, dry syrups, gripe water, and oral liquids and powders, targeting areas such as antibiotics, anti-diabetics, and cardiovascular health. Beyond traditional pharmaceuticals, Kilitch offers effervescent tablets and powders, exemplified by products like ROIPAR, DUREGRA, ROIVIT, and PH-7, as well as nutritional products such as CELTINE. Their innovative solutions include C-Seal, a topical skin adhesive designed for closing wounds without sutures. Furthermore, their product range extends to cosmetics and herbal remedies, encompassing various oils, lotions, liquids, creams, and pastes for skin, personal, and hair care, alongside herbal supplements for conditions like sore throat, prostate issues, diabetes, obesity, and libido enhancement.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +10.01% | +14.23% | +25.16% | +2.72% | -4.88% | -3.45% | -23.08% | +54.89% | +105.17% | +812.85% | +166.74% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+18.7% ★ Q1'26: +46.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+9.7% Q1'26: +26.6% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+2.6% Q1'26: -64.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+14.0% ★ Q1'26: +23.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+8.5% ★ Q1'26: +21.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+5.2% Q1'26: +6.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.42× Q1'26: 1.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
190.27M
est: 320.76M (-40.7%)
|
1.54B
est: 1.65B (-6.9%)
|
1.98B
est: 2.22B (-10.7%)
|
2.94B
2.94B – 2.94B
+32.4% YoY
|
| EBITDA |
-7.86M
est: 50.33M (-115.6%)
|
287.43M
est: 258.92M (+11.0%)
|
426.26M
est: 348.36M (+22.4%)
|
461.34M
461.34M – 461.34M
+32.4% YoY
|
| EBIT |
-26.40M
est: 43.04M (-161.3%)
|
252.84M
est: 221.41M (+14.2%)
|
395.16M
est: 297.89M (+32.6%)
|
394.51M
394.51M – 394.51M
+32.4% YoY
|
| Net Income |
-2.89M
est: 58.74M (-104.9%)
|
146.01M
est: 234.84M (-37.8%)
|
267.01M
est: 382.82M (-30.3%)
|
492.20M
492.20M – 492.20M
+28.6% YoY
|
| SGA |
6.65M
est: 17.54M (-62.1%)
|
48.73M
est: 90.25M (-46.0%)
|
312.74M
est: 121.43M (+157.6%)
|
160.81M
160.81M – 160.81M
+32.4% YoY
|
| EPS |
-0.11
est: 3.65 (-103.0%)
|
4.49
est: 7.30 (-38.6%)
|
8.12
est: 11.90 (-31.8%)
|
15.30
15.30 – 15.30
+28.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bhavin Mukund Mehta | Whole-time Director | 8M | male |
| Mukund Prataprai Mehta | Executive Chairman & MD | 6M | male |
| Mira Bhavin Mehta | MD & Director | 2M | female |
| Sunil Sureshji Jain | Chief Financial Officer | 2M | male |
| Pushpa Nyoupane | Company Secretary & Compliance Officer | — | female |
| Rajesh Khatri | General Manager - Administration | — | — |
| Tajouddin Ansari | VP-Marketing & Operation | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KILITCH.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
